Market revenue in 2023 | USD 134.6 million |
Market revenue in 2030 | USD 331.9 million |
Growth rate | 13.8% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase IV |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 49.26% in 2023. Horizon Databook has segmented the Argentina cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Argentina was not well known as an outsourcing location until just a few years ago, but the combination of good healthcare infrastructure mainly national clinical trial standards compatible with international norms as well as easy recruitment of patients has led to speedy growth in the CRO industry in Argentina. The government has also set up a series of sites of government-run clinical investigative sites (ANMAT sites) in high population urban areas.
The biotechnology and pharmaceutical industries are also preferring Argentina for clinical research due to easy patient recruitment. Also, people in Argentina do not have health coverage and in some cases has very limited access to basic healthcare. Hence, there are huge treatment-naïve potential patients to recruit for cell and gene therapy clinical trials.
Also, a large number of CROs such as Charles Liver Laboratories; Latin Clin; EGCP; Quintiles: Blanchard & Asociados; and Active have operations in Argentina. The Ministry of Health in Argentina issued a new regulation that reduces the timeline for the approval of cell and gene therapy clinical trials from 16 working days to 70 days or less.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Argentina cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account